Similar glycemic benefits were reported with use of the OmniPod 5 (Insulet Corp., San Diego, CA)52 and the Loop open source hybrid closed loop system (LoopDocs).53 Note that insulin-requiring patients with T2D on MDI therapy currently qualify for the use of CGM, but most Medicare beneficiaries do not qualify for insulin pump use. This evidence concerns the gene INS and type 2 diabetes mellitus.